Gamma Vinyl GABA
FDA's Peripheral and Central Nervous System Drugs Advisory Cmte. will review ongoing studies of Merrell-Dow's IND anticonvulsant at Oct. 18 meeting. FDA previously asked the cmte. to review animal data on the drug in May 1984. At that time, the cmte. recommended continued human testing and parallel animal toxicity studies. FDA says that Merrell-Dow has informed the agency that "interim sacrifices of monkeys have detected vacuoles." FDA is asking for another opinion from the advisory cmte. on the continuation of testing.
You may also be interested in...
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.
After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.